Dr. Rajesh is a veteran stem mobile biologist, cancer immunologist, and innovator in the directed differentiation of human pluripotent stem cells (iPSCs)


VANCOUVER, BC , April 6, 2022 /PRNewswire/ — Notch Therapeutics, Inc., a biotechnology firm acquiring renewable, induced pluripotent stem cell (iPSC)-derived mobile therapies for cancer, is delighted to announce the appointment of Deepika Rajesh as VP, Stem Mobile Biology and Developmental Immunology. Dr. Rajesh joins Notch from FUJIFILM Cellular Dynamics, Inc. (FCDI), exactly where she was most lately Senior Director, Investigate & Development. Dr. Rajesh will be primarily based in Notch’s new exploration and development facility in Vancouver.


“The individuals who perform at Notch are some of the most revolutionary minds in biotech todaya equilibrium of seasoned field veterans and rising younger talentand we are delighted to welcome Deepika to the team,” explained David Major, President and Main Executive Officer of Notch. “Deepika’s profession has focused on the advanced biology we’re building to professional standards, and we are grateful for her leadership and experience as we utilize our proprietary technology to increase the advantages of mobile therapies.”


Dr. Rajesh is a stem mobile biologist and cancer immunologist with extra than 20 several years of encounter major groups producing revolutionary stem mobile items. She brings to Notch a history of specialized innovation that includes more than 20 granted and pending patent programs around the globe. Her investigate has concentrated principally on reprogramming several somatic cell types into human pluripotent stem cells (iPSCs) and their subsequent differentiation into hematopoietic, cardiovascular, neural, hepatic, and pancreatic lineages. Above the study course of her occupation, she has managed multidisciplinary teams in study, mental assets, manufacturing, and high quality command to start a variety of iPSC-derived cell types for disorder modeling and drug discovery markets. Dr. Rajesh received a Ph.D. in Utilized Biology from the College of Mumbai, India, and completed her postdoctoral fellowship at the College of WisconsinMadison.


“I’ve invested additional than 25 a long time investigating the immune system’s response to cancer and fully grasp the transformational advantages cell therapies give around present specifications of treatment,” reported Dr. Rajesh. “Notch’s technological innovation platform unlocks the capability to generate T cells and other immune cells from renewable stem cell strains, and I am psyched to be playing a component in developing potential-technology mobile therapies that will alter the way we address and get rid of most cancers.”


About Notch Therapeutics

Notch is an early-stage biotech business doing the job to maximize the reward of mobile therapies through a proprietary?T mobile-production platform that brings together advanced merchandise style with commercial-appropriate procedures to enhance individual outcomes.?Notch’s iPSC-centered technological innovation system permits for precision regulate of notch signaling, which gets rid of several essential limiting components in the progress of cell therapies, delivering the capability to structure and manufacture a uniform and limitless source of therapeutic T cells. www.notchtx.com.


Media Get in touch with:

Megan Helmer

Puzzlewood Interaction Inc.

1.604.240.5223

[email protected]


Look at initial content:https://www.prnewswire.com/news-releases/notch-therapeutics-welcomes-deepika-rajesh-as-vp-stem-cell-biology–developmental-immunology-301518754.html


Supply Notch Therapeutics